Literature DB >> 29247347

Patient and physician perspectives on the impact of health-related quality of life in Mexican patients with ANCA-associated vasculitis.

Andrea Hinojosa-Azaola1, Ariadna Jiménez-González1, Natasha Alcocer-Castillejos2.   

Abstract

The objective of this study is to describe aspects of health-related quality of life (HRQOL) in Mexican patients with antineutrophil cytoplasmic-associated vasculitis (AAV). Cross-sectional comparison study includes patients with established AAV and a comparison group with rheumatoid arthritis (RA), chronic kidney disease (CKD), and healthy subjects. Variables considered were: socio-demographic data, comorbidities, laboratory, disease activity, damage, and Physician's and Patient's Global Assessment (PhGA and PtGA). The following measurements were done: Pittsburg sleep quality index, Multidimesional Fatigue Inventory (MFI-20), Hospital Anxiety and Depression Scale, Short Form 36 questionnaire (SF-36), and Health Assessment Questionnaire. 60 patients with AAV were included, median age 54 years, and 60% female. Significant differences were found only in the bodily pain domain of the SF-36 (p = 0.01). Aspects of disease relevant for AAV patients were: fatigue and lack of energy; visual abnormalities; neuropathy; renal impairment; arthritis, and sinusitis. Greater total score on MFI-20 (p < 0.001) and worse PtGA (p = 0.01) were associated with worse physical health. Higher PhGA values were associated with worse physical quality of life (p = 0.01). Greater fatigue score (p = 0.002), greater anxiety-depression score (p = 0.005), and worse PtGA (p = 0.01) were associated with worse mental health quality of life. No differences were found in prevalence of sleep impairment, anxiety, depression, or disability between groups. AAV patients experienced more general and physical fatigue (p < 0.0001), and reduced activity (p = 0.01) than healthy subjects, but similar to RA and CKD patients. Vasculitis has negative effects on patients' physical and mental HRQOL.

Entities:  

Keywords:  ANCA; Patient-reported outcomes; Quality of life; Vasculitis

Mesh:

Year:  2017        PMID: 29247347     DOI: 10.1007/s00296-017-3904-1

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  40 in total

1.  [Evaluation of health status using Survey SF-36: preliminary results in Mexico].

Authors:  M A Zúniga; G T Carrillo-Jiménez; P J Fos; B Gandek; M R Medina-Moreno
Journal:  Salud Publica Mex       Date:  1999 Mar-Apr

Review 2.  Optimisation of vasculitis disease assessments in clinical trials, clinical care and long-term databases.

Authors:  C Ponte; J Sznajd; L O'Neill; R A Luqmani
Journal:  Clin Exp Rheumatol       Date:  2014-10-30       Impact factor: 4.473

3.  The effect of medication-related support on the quality of life of patients with vasculitis in relapse and remission.

Authors:  Delesha M Carpenter; Jessica A Kadis; Robert F Devellis; Susan L Hogan; Joanne M Jordan
Journal:  J Rheumatol       Date:  2011-02-01       Impact factor: 4.666

Review 4.  Systemic vasculitis: how little we know about their societal and economic burden.

Authors:  Leopoldo Trieste; Ilaria Palla; Chiara Baldini; Rosaria Talarico; Lucia D'Angiolella; Marta Mosca; Giuseppe Turchetti
Journal:  Clin Exp Rheumatol       Date:  2012-10-16       Impact factor: 4.473

5.  Fatigue: a principal contributor to impaired quality of life in ANCA-associated vasculitis.

Authors:  Neil Basu; Gareth T Jones; Nick Fluck; Alan G MacDonald; Dong Pang; Paula Dospinescu; David M Reid; Gary J Macfarlane
Journal:  Rheumatology (Oxford)       Date:  2010-04-17       Impact factor: 7.580

6.  Health-related quality of life for patients with vasculitis and their spouses.

Authors:  Delesha M Carpenter; Carolyn T Thorpe; Megan Lewis; Robert F Devellis; Susan L Hogan
Journal:  Arthritis Rheum       Date:  2009-02-15

7.  [Colombian validation of the Pittsburgh Sleep Quality Index].

Authors:  F Escobar-Córdoba; J Eslava-Schmalbach
Journal:  Rev Neurol       Date:  2005 Feb 1-15       Impact factor: 0.870

Review 8.  Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody-associated Vasculitis Using the OMERACT Process.

Authors:  Joanna C Robson; Nataliya Milman; Gunnar Tomasson; Jill Dawson; Peter F Cronholm; Katherine Kellom; Judy Shea; Susan Ashdown; Maarten Boers; Annelies Boonen; George C Casey; John T Farrar; Don Gebhart; Jeffrey Krischer; Georgia Lanier; Carol A McAlear; Jacqueline Peck; Antoine G Sreih; Peter S Tugwell; Raashid A Luqmani; Peter A Merkel
Journal:  J Rheumatol       Date:  2015-09-01       Impact factor: 4.666

9.  The characterisation and determinants of quality of life in ANCA associated vasculitis.

Authors:  Neil Basu; Andrew McClean; Lorraine Harper; Esther Nicole Amft; Neeraj Dhaun; Raashid A Luqmani; Mark A Little; David Rw Jayne; Oliver Flossmann; John McLaren; Vinod Kumar; Lars P Erwig; David M Reid; Gareth T Jones; Gary J Macfarlane
Journal:  Ann Rheum Dis       Date:  2013-01-25       Impact factor: 19.103

10.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Authors:  J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts
Journal:  Arthritis Rheum       Date:  2013-01
View more
  6 in total

1.  Predictor of depressive disorders in patients with antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Jan-Di Yun; Junghee Ha; Solah Kim; Hyung Ah Park; Juyoung Yoo; Sung Soo Ahn; Seung Min Jung; Jason Jungsik Song; Yong-Beom Park; Sang-Won Lee
Journal:  Clin Rheumatol       Date:  2019-07-16       Impact factor: 2.980

2.  Birmingham vasculitis activity score and the short form 36-item health survey predict current depressive disorders in patients with antineutrophil cytoplasmic antibody-associated vasculitis during the SARS-CoV-2 pandemic.

Authors:  Jan-Di Yun; Joo Hye Lee; Jung Yoon Pyo; Sung Soo Ahn; Jason Jungsik Song; Yong-Beom Park; Sang-Won Lee
Journal:  Z Rheumatol       Date:  2022-06-24       Impact factor: 1.530

3.  Physician Global Assessment as a Disease Activity Measure for Relapsing Polychondritis.

Authors:  Emily Rose; Marcela A Ferrada; Kaitlin A Quinn; Wendy Goodspeed; Laurent Arnaud; Aman Sharma; Hajime Yoshifuji; Jeff Kim; Clint Allen; Arlene Sirajuddin; Marcus Chen; Peter C Grayson
Journal:  Arthritis Care Res (Hoboken)       Date:  2022-04-29       Impact factor: 5.178

4.  The prevalence and impact of depression in primary systemic vasculitis: a systematic review and meta-analysis.

Authors:  Bradley Pittam; Sonal Gupta; Ashar E Ahmed; David M Hughes; Sizheng Steven Zhao
Journal:  Rheumatol Int       Date:  2020-06-04       Impact factor: 2.631

5.  Healthcare and economic burden of ANCA-associated vasculitis in Italy: an integrated analysis from clinical and administrative databases.

Authors:  Luca Quartuccio; Elena Treppo; Francesca Valent; Salvatore De Vita
Journal:  Intern Emerg Med       Date:  2020-07-14       Impact factor: 3.397

Review 6.  Therapy of ocular complications in ANCA+ associated vasculitis.

Authors:  Simion Macarie Sorin; Mihăilă Răzvan-Marian; Mariana Macarie Daniela; Toc Dan-Alexandru
Journal:  Rom J Ophthalmol       Date:  2021 Jan-Mar
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.